Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes

Jiyoung Kim, Sekyung Lee, Sooyoun Bae, Min Young Choi, Jeonghui Lee, Seung Pil Jung, Sangmin Kim, Jun Ho Choe, Jung Han Kim, Jee Soo Kim, Jeong Eon Lee, Seok Jin Nam, Jung Hyun Yang

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Breast cancer screening programs make it possible to detect early cancer, thus reducing breast cancer mortality. We studied the clinicopathologic characteristics and prognosis of screen-detected invasive breast cancer compared with symptomatic breast cancer. And we compared the result according to molecular subtypes (luminal A, luminal B, Her2, and triple negative), with the goal of identifying the role of screening in each subtypes. From January 2002 to June 2008, 3,141 patients who underwent surgery for the treatment of invasive ductal carcinoma at Samsung Medical Center were included. Among them, 1,025 patients were screen-detected, and 2,116 patients who were screened over 2 years or never were symptomatic. We retrospectively reviewed the clinical and pathologic data. Screen-detected breast cancer was associated with older age, smaller tumor size, more hormone-receptor positive, less lymph node involvement, earlier stage, and reduced mortality compared with symptomatic breast cancer (P < 0.001). According to the molecular subtype, luminal A was most common (63.6%) and showed the most obvious survival benefit in screen-detected tumors in comparison with symptomatic tumors (5-year OS: 99.7 vs. 96.5%, 5-year DFS: 96.4 vs. 90.7%). Screen detection was independently associated with improved overall and disease-free survival outcomes after adjustment for covariates (HR 0.32, P = 0.035; HR 0.58, P = 0.020, respectively) only in the luminal A subtype. Differences in pathological features such as tumor size, nodal status, grade, and age at diagnosis with different molecular subtype distributions may explain the survival advantage of patients with screen-detected breast cancer. Screening programs seem to have a different efficacy depending on the molecular subtype of the breast cancer, especially in the luminal A subtype, for which screen detection acts as an independent prognostic factor itself.

Original languageEnglish
Pages (from-to)527-540
Number of pages14
JournalBreast Cancer Research and Treatment
Volume131
Issue number2
DOIs
Publication statusPublished - 2012 Jan 1
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasms
Ductal Carcinoma
Survival
Mortality
Early Detection of Cancer
Disease-Free Survival
Lymph Nodes
Hormones

Keywords

  • Breast cancer
  • Molecular subtype
  • Prognosis
  • Screen-detected

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. / Kim, Jiyoung; Lee, Sekyung; Bae, Sooyoun; Choi, Min Young; Lee, Jeonghui; Jung, Seung Pil; Kim, Sangmin; Choe, Jun Ho; Kim, Jung Han; Kim, Jee Soo; Lee, Jeong Eon; Nam, Seok Jin; Yang, Jung Hyun.

In: Breast Cancer Research and Treatment, Vol. 131, No. 2, 01.01.2012, p. 527-540.

Research output: Contribution to journalArticle

Kim, J, Lee, S, Bae, S, Choi, MY, Lee, J, Jung, SP, Kim, S, Choe, JH, Kim, JH, Kim, JS, Lee, JE, Nam, SJ & Yang, JH 2012, 'Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes', Breast Cancer Research and Treatment, vol. 131, no. 2, pp. 527-540. https://doi.org/10.1007/s10549-011-1836-0
Kim, Jiyoung ; Lee, Sekyung ; Bae, Sooyoun ; Choi, Min Young ; Lee, Jeonghui ; Jung, Seung Pil ; Kim, Sangmin ; Choe, Jun Ho ; Kim, Jung Han ; Kim, Jee Soo ; Lee, Jeong Eon ; Nam, Seok Jin ; Yang, Jung Hyun. / Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. In: Breast Cancer Research and Treatment. 2012 ; Vol. 131, No. 2. pp. 527-540.
@article{0e3ddd9716554bb99f2873e9a699ef16,
title = "Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes",
abstract = "Breast cancer screening programs make it possible to detect early cancer, thus reducing breast cancer mortality. We studied the clinicopathologic characteristics and prognosis of screen-detected invasive breast cancer compared with symptomatic breast cancer. And we compared the result according to molecular subtypes (luminal A, luminal B, Her2, and triple negative), with the goal of identifying the role of screening in each subtypes. From January 2002 to June 2008, 3,141 patients who underwent surgery for the treatment of invasive ductal carcinoma at Samsung Medical Center were included. Among them, 1,025 patients were screen-detected, and 2,116 patients who were screened over 2 years or never were symptomatic. We retrospectively reviewed the clinical and pathologic data. Screen-detected breast cancer was associated with older age, smaller tumor size, more hormone-receptor positive, less lymph node involvement, earlier stage, and reduced mortality compared with symptomatic breast cancer (P < 0.001). According to the molecular subtype, luminal A was most common (63.6{\%}) and showed the most obvious survival benefit in screen-detected tumors in comparison with symptomatic tumors (5-year OS: 99.7 vs. 96.5{\%}, 5-year DFS: 96.4 vs. 90.7{\%}). Screen detection was independently associated with improved overall and disease-free survival outcomes after adjustment for covariates (HR 0.32, P = 0.035; HR 0.58, P = 0.020, respectively) only in the luminal A subtype. Differences in pathological features such as tumor size, nodal status, grade, and age at diagnosis with different molecular subtype distributions may explain the survival advantage of patients with screen-detected breast cancer. Screening programs seem to have a different efficacy depending on the molecular subtype of the breast cancer, especially in the luminal A subtype, for which screen detection acts as an independent prognostic factor itself.",
keywords = "Breast cancer, Molecular subtype, Prognosis, Screen-detected",
author = "Jiyoung Kim and Sekyung Lee and Sooyoun Bae and Choi, {Min Young} and Jeonghui Lee and Jung, {Seung Pil} and Sangmin Kim and Choe, {Jun Ho} and Kim, {Jung Han} and Kim, {Jee Soo} and Lee, {Jeong Eon} and Nam, {Seok Jin} and Yang, {Jung Hyun}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/s10549-011-1836-0",
language = "English",
volume = "131",
pages = "527--540",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes

AU - Kim, Jiyoung

AU - Lee, Sekyung

AU - Bae, Sooyoun

AU - Choi, Min Young

AU - Lee, Jeonghui

AU - Jung, Seung Pil

AU - Kim, Sangmin

AU - Choe, Jun Ho

AU - Kim, Jung Han

AU - Kim, Jee Soo

AU - Lee, Jeong Eon

AU - Nam, Seok Jin

AU - Yang, Jung Hyun

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Breast cancer screening programs make it possible to detect early cancer, thus reducing breast cancer mortality. We studied the clinicopathologic characteristics and prognosis of screen-detected invasive breast cancer compared with symptomatic breast cancer. And we compared the result according to molecular subtypes (luminal A, luminal B, Her2, and triple negative), with the goal of identifying the role of screening in each subtypes. From January 2002 to June 2008, 3,141 patients who underwent surgery for the treatment of invasive ductal carcinoma at Samsung Medical Center were included. Among them, 1,025 patients were screen-detected, and 2,116 patients who were screened over 2 years or never were symptomatic. We retrospectively reviewed the clinical and pathologic data. Screen-detected breast cancer was associated with older age, smaller tumor size, more hormone-receptor positive, less lymph node involvement, earlier stage, and reduced mortality compared with symptomatic breast cancer (P < 0.001). According to the molecular subtype, luminal A was most common (63.6%) and showed the most obvious survival benefit in screen-detected tumors in comparison with symptomatic tumors (5-year OS: 99.7 vs. 96.5%, 5-year DFS: 96.4 vs. 90.7%). Screen detection was independently associated with improved overall and disease-free survival outcomes after adjustment for covariates (HR 0.32, P = 0.035; HR 0.58, P = 0.020, respectively) only in the luminal A subtype. Differences in pathological features such as tumor size, nodal status, grade, and age at diagnosis with different molecular subtype distributions may explain the survival advantage of patients with screen-detected breast cancer. Screening programs seem to have a different efficacy depending on the molecular subtype of the breast cancer, especially in the luminal A subtype, for which screen detection acts as an independent prognostic factor itself.

AB - Breast cancer screening programs make it possible to detect early cancer, thus reducing breast cancer mortality. We studied the clinicopathologic characteristics and prognosis of screen-detected invasive breast cancer compared with symptomatic breast cancer. And we compared the result according to molecular subtypes (luminal A, luminal B, Her2, and triple negative), with the goal of identifying the role of screening in each subtypes. From January 2002 to June 2008, 3,141 patients who underwent surgery for the treatment of invasive ductal carcinoma at Samsung Medical Center were included. Among them, 1,025 patients were screen-detected, and 2,116 patients who were screened over 2 years or never were symptomatic. We retrospectively reviewed the clinical and pathologic data. Screen-detected breast cancer was associated with older age, smaller tumor size, more hormone-receptor positive, less lymph node involvement, earlier stage, and reduced mortality compared with symptomatic breast cancer (P < 0.001). According to the molecular subtype, luminal A was most common (63.6%) and showed the most obvious survival benefit in screen-detected tumors in comparison with symptomatic tumors (5-year OS: 99.7 vs. 96.5%, 5-year DFS: 96.4 vs. 90.7%). Screen detection was independently associated with improved overall and disease-free survival outcomes after adjustment for covariates (HR 0.32, P = 0.035; HR 0.58, P = 0.020, respectively) only in the luminal A subtype. Differences in pathological features such as tumor size, nodal status, grade, and age at diagnosis with different molecular subtype distributions may explain the survival advantage of patients with screen-detected breast cancer. Screening programs seem to have a different efficacy depending on the molecular subtype of the breast cancer, especially in the luminal A subtype, for which screen detection acts as an independent prognostic factor itself.

KW - Breast cancer

KW - Molecular subtype

KW - Prognosis

KW - Screen-detected

UR - http://www.scopus.com/inward/record.url?scp=84856221264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856221264&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1836-0

DO - 10.1007/s10549-011-1836-0

M3 - Article

C2 - 22042364

AN - SCOPUS:84856221264

VL - 131

SP - 527

EP - 540

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -